These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 47001)

  • 21. Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors.
    Presthus J; Holmsen R
    Acta Neurol Scand; 1974; 50(6):774-90. PubMed ID: 4440452
    [No Abstract]   [Full Text] [Related]  

  • 22. Letter: Diphasic dyskinesia during levodopa therapy.
    Barbeau A
    Lancet; 1975 Mar; 1(7909):756. PubMed ID: 47527
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 24. Zotepine in levodopa-induced Psychosis.
    Spieker S; Stetter F; Klockgether T
    Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
    [No Abstract]   [Full Text] [Related]  

  • 25. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A
    Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract]   [Full Text] [Related]  

  • 26. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 28. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial.
    Olsson JE
    Adv Neurol; 1990; 53():421-3. PubMed ID: 2239483
    [No Abstract]   [Full Text] [Related]  

  • 29. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
    Meiler B; Andrich J; Müller T
    Mov Disord; 2008 Jan; 23(1):145-6. PubMed ID: 17987653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Sinemet 25/100 in Parkinson's disease.
    Ulm G; Gerdes U; Lehmann K
    Adv Neurol; 1984; 40():541-7. PubMed ID: 6695634
    [No Abstract]   [Full Text] [Related]  

  • 32. [Combined treatment of parkinsonism with L-dopa and Parkopan].
    Lukasiewicz K
    Wiad Lek; 1977 May; 30(10):775-7. PubMed ID: 867994
    [No Abstract]   [Full Text] [Related]  

  • 33. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 34. [Results of L-dopa treatment of parkinsonism].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(2):153-8. PubMed ID: 1153050
    [No Abstract]   [Full Text] [Related]  

  • 35. High-level levodopa therapy in Parkinson's disease: five years later.
    Barbeau A
    Trans Am Neurol Assoc; 1974; 99():160-3. PubMed ID: 4463526
    [No Abstract]   [Full Text] [Related]  

  • 36. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease].
    Poewe W; Kleedorfer B; Gerstenbrand F
    Nervenarzt; 1989 May; 60(5):294-8. PubMed ID: 2739822
    [No Abstract]   [Full Text] [Related]  

  • 38. Severe ataxic polyneuropathy associated with chronic levodopa use in Parkinson's disease.
    Kimber T; Blumbergs P; Thompson P
    Parkinsonism Relat Disord; 2013 Sep; 19(9):847-9. PubMed ID: 23746939
    [No Abstract]   [Full Text] [Related]  

  • 39. Treating parkinsonism with L-dopa and carboxylase inhibitor.
    Shau-Fong K; Ho YM
    Mod Med Asia; 1977 Sep; 13(9):23-5. PubMed ID: 600260
    [No Abstract]   [Full Text] [Related]  

  • 40. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.